A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

Article Abstract:

The final results of the European Study Group for Pancreatic Cancer 1 Trial are reported and the interim results are updated. It is concluded that adjuvant chemotherapy has a significant survival benefit in patients with resected pancreatic cancer, whereas adjuvant chemoradiotherapy has a deleterious effect on survival.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer

Article Abstract:

A study reports on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer. Rofecoxib is found to be associated with an increased frequency of adverse cardiovascular events with a median study treatment of 7.4 months' duration.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Adjuvant therapy for pancreatic cancer-the debate continues

Article Abstract:

An updated and improved analysis of the European Study Group for Pancreatic Cancer (ESPAC-1) trial, the largest randomized trial of adjuvant therapy for pancreatic cancer, is reported. The attempts made to correct some of the limitations of the previous report are discussed.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: